Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
CytRx reports net loss of $0.6 million for third quarter 2011

CytRx reports net loss of $0.6 million for third quarter 2011

PKM2 enzyme has important non-metabolic functions in cancer formation

PKM2 enzyme has important non-metabolic functions in cancer formation

ARIAD reports net income of $13.9 million for third quarter 2011

ARIAD reports net income of $13.9 million for third quarter 2011

New library for development of targeted cancer drugs

New library for development of targeted cancer drugs

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Taxoxifen combined with dasatinib reverses chemo-resistance in breast cancer cells

Taxoxifen combined with dasatinib reverses chemo-resistance in breast cancer cells

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Medco announces new offerings within Advanced Oncology Solutions

Medco announces new offerings within Advanced Oncology Solutions

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

LLS announces four new Academic Concierge partnerships for cancer drug development

LLS announces four new Academic Concierge partnerships for cancer drug development

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

CytRx reports $6.3 million net loss for first quarter 2011

CytRx reports $6.3 million net loss for first quarter 2011

Scientists identify new treatment target for squamous cell lung cancer

Scientists identify new treatment target for squamous cell lung cancer

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

Combination therapy may overcome Herceptin-resistant breast cancer

Combination therapy may overcome Herceptin-resistant breast cancer

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx's bafetinib helps reduce skeletal complications in cancer patients

CytRx's bafetinib helps reduce skeletal complications in cancer patients

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia